Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Species differences in phenazeram kinetics and metabolism
- V. Zherdev, S. Caccia, S. Garattini, A. L. Ékonomov
- Biology, MedicineEuropean Journal of Drug Metabolism and…
The results suggest that 3-OH- phenazepam might contribute to the overall pharmacological effects of the parent compound in those species in which it accumulates in significant amounts.
[Comparative pharmacokinetics of dihydroquercetin in rats upon peroral administration of a parent compound and liposomal flamen D].
- V. Zherdev, G. Kolyvanov, V. V. Gorlov
- Chemistry, BiologyEksperimental'naia i klinicheskaia farmakologiia
The pharmacokinetics of dihydroquercetin (DHQ) in the forms of parent substance and a new liposomal formulation (Flamena D) have been studied in rats upon single peroral administration in a dose of…
[Bemetil pharmacokinetics in an experiment on rats].
- S. Boiko, I. Bobkov, V. Zherdev, A. A. Dvorianinov
- Biology, ChemistryFarmakologiia i toksikologiia
- 1 September 1987
It was found that at intragastric administration the drug rapidly appeared in the systemic circulation, reached the maximal concentration in one hour; the character of bemetil elimination from the blood was biexponential at both routes of administration.
Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo‐prolylglycine in rat brain
Regional and Subcellular Localization of Cycloprolylglycine in Rat Brain
- S. Boiko, T. Gudasheva, M. V. Vichuzhanin, V. Zherdev, S. Seredenin
- BiologyBulletin of Experimental Biology and Medicine
- 28 October 2010
HPLC analysis showed that endogenous cyclopeptide cycloprolylglycine exhibiting mnemotropic and anxiolytic properties is nonuniformly distributed between brain structures in rats: its contents in the…
The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-l-prolylglycine
The metabolism of a new piracetam analogue, the dipeptide cognitive enhancer N-phenylacetyl-l-prolylglycine ethyl ester (GVS-111), was studied in vivo and could be considered as evidence that G VS-111 is prodrug which converts in the body to cyclo- Prolyl Glycine, and which is identical to the endogenous cyclopeptide that produces the nootropic activity.
Preclinical Pharmacokinetic and Pharmacodynamic Studies of Pharmaceutical Compositions of the Dipeptide Anxiolytic GB-115
Four pharmaceutical compositions for oral use that contained the dipeptide anxiolytic GB-115 as the active ingredient underwent preclinical trials in male laboratory white rats and it was shown that compositions 2 and 4 had advantages according to the main pharmacokinetic characteristics reflecting the bioavailability ofGB-115.
Comparative Preclinical Pharmacokinetics and Bioavailability of Antidepressant GSB-106 Tablet Form
- G. Kolyvanov, V. Zherdev, V. Bueva
- Chemistry, BiologyBulletin of Experimental Biology and Medicine
- 1 September 2019
Pharmacokinetics and relative bioavailability of antidepressant GSB-106 (hexamethylendiamide bis-(N-monosuccinyl-L-seryl-L-lysine) were determined in rabbits after single oral administration of the…
The relationship between the content of the potential psychopharmacological agent cyclo-L-prolylglycine in the brain of experimental animals and its antihypoxic effect
HPLC-MS method development and validation for simultaneous quantitation of GZK-111 and CPG compounds in rat plasma
The technique of quantitative determination of GZK-111 and CPG compounds in rat blood plasma has been developed. The analysis was carried out using the combined method of high-performance liquid…